IL267934B2 - Glyceryl 3-hydroxybutyrate Traumatic brain injury - Google Patents

Glyceryl 3-hydroxybutyrate Traumatic brain injury

Info

Publication number
IL267934B2
IL267934B2 IL267934A IL26793419A IL267934B2 IL 267934 B2 IL267934 B2 IL 267934B2 IL 267934 A IL267934 A IL 267934A IL 26793419 A IL26793419 A IL 26793419A IL 267934 B2 IL267934 B2 IL 267934B2
Authority
IL
Israel
Prior art keywords
hydroxybutyrate
glyceryl
composition
tbi
ester
Prior art date
Application number
IL267934A
Other languages
English (en)
Hebrew (he)
Other versions
IL267934B1 (en
IL267934A (en
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Sami Hashim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc, Sami Hashim filed Critical Neuroenergy Ventures Inc
Publication of IL267934A publication Critical patent/IL267934A/en
Publication of IL267934B1 publication Critical patent/IL267934B1/en
Publication of IL267934B2 publication Critical patent/IL267934B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL267934A 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrate Traumatic brain injury IL267934B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/404,396 US9925164B1 (en) 2017-01-12 2017-01-12 Glyceryl 3-hydroxybutyrates for traumatic brain injury
PCT/US2017/063853 WO2018132189A1 (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury

Publications (3)

Publication Number Publication Date
IL267934A IL267934A (en) 2019-09-26
IL267934B1 IL267934B1 (en) 2024-05-01
IL267934B2 true IL267934B2 (en) 2024-09-01

Family

ID=61633011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267934A IL267934B2 (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrate Traumatic brain injury

Country Status (11)

Country Link
US (3) US9925164B1 (enExample)
EP (1) EP3568129A4 (enExample)
JP (1) JP7278593B2 (enExample)
KR (1) KR102443942B1 (enExample)
CN (1) CN110114067A (enExample)
BR (1) BR112019014128A2 (enExample)
CA (1) CA3046355C (enExample)
IL (1) IL267934B2 (enExample)
MX (1) MX391851B (enExample)
MY (1) MY207193A (enExample)
WO (1) WO2018132189A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
CA3021784A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12091383B2 (en) * 2019-01-17 2024-09-17 Ketolipix Therapeutics Gmbh Method for producing lipids comprising structural units based on glycerides of hydroxycarboxylc acids
JP7235873B2 (ja) * 2019-01-17 2023-03-08 アイオーアイ オレオ ゲーエムベーハー ヒドロキシカルボン酸のグリセリドの製造方法
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
IL288343B2 (en) * 2019-05-30 2024-04-01 Neuroenergy Ventures Inc Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks
WO2020249195A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von ketocarbonsäuren
CN114008015B (zh) * 2019-06-12 2024-02-20 凯托利皮克斯治疗有限责任公司 羟基羧酸多元醇酯、特别是聚甘油酯的制备方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
JP2023543110A (ja) * 2020-07-13 2023-10-13 ケトリピックス セラポーティクス ゲーエムベーハー オキソブタノールでエステル化されたポリグリセロールエステルを製造する方法
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US20240342121A1 (en) * 2021-07-09 2024-10-17 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
IL312317B2 (en) 2021-11-12 2025-04-01 Arxada Ag Polyol-derived compounds
US20250002446A1 (en) 2021-11-26 2025-01-02 Arxada Ag Acetoacetate Based Ketals
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2023167989A2 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2011101171A1 (en) * 2010-02-22 2011-08-25 Tdeltas Limited Nutritional composition
WO2015034812A2 (en) * 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
JP4740426B2 (ja) * 1997-03-17 2011-08-03 ビーティージー・インターナショナル・リミテッド 治療用組成物
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
KR20090003148A (ko) 2006-04-03 2009-01-09 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도
CA2684213A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
JP2009173766A (ja) 2008-01-24 2009-08-06 Ono Kogei Kk 炭素繊維含有コーティング組成物およびその調製方法
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EA201190115A1 (ru) 2009-01-24 2012-02-28 ФИТОФАРМ ПиЭлСи Лечение расстройств, опосредованных нейротрофическим фактором
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
DK2914251T3 (da) 2012-11-05 2019-11-04 Us Health Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
PE20151949A1 (es) 2013-03-19 2016-01-05 Univ South Florida Composiciones y metodos para producir cetosis elevada y sostenida
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
WO2017011294A1 (en) 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
WO2017165445A1 (en) 2016-03-21 2017-09-28 Csilla Ari D'agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20180055797A1 (en) 2016-08-31 2018-03-01 KetoneAid Inc. Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy
CA3036688A1 (en) 2016-09-12 2018-03-15 University Of South Florida Neuroregeneration improved by ketone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2011101171A1 (en) * 2010-02-22 2011-08-25 Tdeltas Limited Nutritional composition
WO2015034812A2 (en) * 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GASIOR MACIEJ, MICHAEL A. ROGAWSKI, AND ADAM L. HARTMAN.:, NEUROPROTECTIVE AND DISEASE-MODIFYING EFFECTS OF THE KETOGENIC DIET, 30 September 2006 (2006-09-30) *
HASHIM, SAMI A., AND THEODORE B. VANITALLIE, KETONE BODY THERAPY: FROM THE KETOGENIC DIET TO THE ORAL ADMINISTRATION OF KETONE ESTER, 1 September 2014 (2014-09-01) *
PILLSBURY LAURA, MARIA ORIA, AND JOHN ERDMAN, EDS.:, NUTRITION AND TRAUMATIC BRAIN INJURY: IMPROVING ACUTE AND SUBACUTE HEALTH OUTCOMES IN MILITARY PERSONNEL., 31 December 2011 (2011-12-31) *
PRIN MAYUMI L., AND JOYCE H. MATSUMOTO:, THE COLLECTIVE THERAPEUTIC POTENTIAL OF CEREBRAL KETONE METABOLISM IN TRAUMATIC BRAIN INJURY, 1 December 2014 (2014-12-01) *
VEECH RICHARD L. ET AL.:, THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE PROVIDES A KEY TO THE DIAGNOSIS AND TREATMENT OF TRAUMATIC BRAIN INJURY, 29 February 2012 (2012-02-29) *
WHITE HAYDEN, AND BALASUBRAMANIAN VENKATESH:, CLINICAL REVIEW: KETONES AND BRAIN INJURY., 6 April 2011 (2011-04-06) *

Also Published As

Publication number Publication date
KR20190104546A (ko) 2019-09-10
US11638702B2 (en) 2023-05-02
US20180193300A1 (en) 2018-07-12
EP3568129A4 (en) 2020-12-09
US9925164B1 (en) 2018-03-27
IL267934B1 (en) 2024-05-01
IL267934A (en) 2019-09-26
MX391851B (es) 2025-03-21
CA3046355A1 (en) 2018-07-19
CA3046355C (en) 2023-08-01
MY207193A (en) 2025-02-05
JP2020504134A (ja) 2020-02-06
MX2019008269A (es) 2019-09-13
US20200297686A1 (en) 2020-09-24
WO2018132189A1 (en) 2018-07-19
CN110114067A (zh) 2019-08-09
KR102443942B1 (ko) 2022-09-15
JP7278593B2 (ja) 2023-05-22
US10736867B2 (en) 2020-08-11
EP3568129A1 (en) 2019-11-20
BR112019014128A2 (pt) 2020-06-16

Similar Documents

Publication Publication Date Title
US11638702B2 (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
Antushevich Fecal microbiota transplantation in disease therapy
JP7108320B2 (ja) 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート
Martinez Restoring the DHA levels in the brains of Zellweger patients
JP2020504134A5 (enExample)
Sears et al. Therapeutic uses of high-dose omega-3 fatty acids to treat comatose patients with severe brain injury
Jahromi et al. Islamic fasting and multiple sclerosis
CN106535919A (zh) 改善脑功能的药剂和预防或治疗认知功能障碍的药剂
Saleh-Ghadimi et al. Effect of flaxseed oil supplementation on anthropometric and metabolic indices in patients with coronary artery disease: a double-blinded randomized controlled trial
US20030096736A1 (en) Lactoferrin for age related disorders in humans
Jiang et al. The effects of two mixed intravenous lipid emulsions on clinical outcomes in infants after gastrointestinal surgery: a prospective, randomized study
Lotfi et al. Biological activities of astaxanthin in the treatment of neurodegenerative diseases
Keskin et al. Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria
HK40012461A (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
Kuźniar et al. Ketogenic diet and intermittent fasting-impact on body weight and various diseases
RU2631887C2 (ru) Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения демиелинизирующих заболеваний живого организма, включая профилактику заболевания
Quertinmount et al. A Novel Approach to Treating Alzheimer's Disease
Lee et al. Association between multioil intravenous lipid emulsion and cholestasis in infants with gastrointestinal disorders: A retrospective cohort study
Yuen et al. Treatment of Iatrogenic Essential Fatty Acid Deficiency with a Lipid-Rich Matrix in a Child with Intestinal Failure-Associated Liver Disease: Case Report
Chandna et al. The Importance of Omega-3 Fatty Acids in the Management and Rehabilitation of Depressive Disorders
le Roux Forget About Alzheimer’s
Voss Hospital Pharmacy Pharmacy Focus
Khorasan et al. Jacobs Journal of Emergency Medicine
Gruenwald et al. Efficacy and tolerability of mussel-Lyprinol® omega-3-complex on inflammatory rheumatoid disorders
Elsharkawy The Ketogenic Diet A review of the use of the ketogenic diet in childhood epilepsy